Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sleep better, age better? study tests urolithin a and fisetin

NCT ID NCT06990256

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study is testing whether two dietary supplements, urolithin A and fisetin, can improve sleep quality and reduce signs of aging in middle-aged and older adults. Eighty participants aged 30-75 with poor sleep will take one of the supplements, a combination, or a placebo daily for 12 weeks. Researchers will measure sleep using questionnaires and overnight monitoring, and check aging markers like inflammation and DNA changes in blood and stool samples.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Urolithin A and Fisetin (dietary supplements)
What this could lead to
If it works, this could point toward a simple nutritional supplement strategy to improve sleep quality and slow certain aspects of aging.
What could go wrong
This is a small, early-phase trial with only 80 participants, so results may not apply to everyone. The supplements may show no benefit over placebo, and long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

83 people

The number who actually took part.

Started

Sep 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 30-75 years; * Total score \> 5 points on the Pittsburgh Sleep Quality Index (PSQI) for sleep quality assessment; * Able to use personal mobile devices for WeChat, internet access, and related operations; * Informed about the intervention trial and willing to undergo sleep monitoring and other examinations during the study; * Commitment to consume coffee, strong tea, or alcohol ≤1 time per week during the trial period; Exclusion Criteria: * Participation in any clinical trials or dietary/exercise intervention programs within the past 3 months or concurrently; * Diagnosis of major mental disorders or family history thereof, or current use of psychotropic drugs or mood-regulating medications; * Experiencing major psychological trauma (e.g., death of a close relative, significant financial loss) personally or within the family in the past 3 months; * Severe diseases affecting inflammatory levels and/or endocrine components (e.g., severe obesity, uncontrolled diabetes or poorly controlled blood glucose, myocardial infarction, cerebral infarction); * Current use of hormonal medications, beta-blockers, steroids, non-steroidal anti-inflammatory drugs (NSAIDs), etc.; * Use of medications potentially affecting sleep or aging biomarkers (e.g., melatonin, antidepressants, anxiolytics) within the past 3 months; * Plans for relocation or long-term travel within the next 6 months, which may hinder continuous intervention and follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Wuchang Hospital Affiliated to Wuhan University of Science and Technology

    Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.